BioMarin's growth narrative is anchored by Voxzogo, which drove revenue acceleration to 19.9% in 2026Q2, but the $5.1B Amicus acquisition has introduced significant integration costs and a debt surge to $4.2B, pressuring near-term margins and earnings quality....
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 19.9% in 2026Q2, but net income fell 81.3% year-over-year to $44.8M due to SG&A spiking to $395.5M, compressing operating margin to 11.2% from 33.5% a year earlier.
BioMarin Pharmaceutical Inc. (BMRN) receives extensive stock analysis, price targets, and earnings estimates, indicating strong investor interest and market visibility.
With offices and facilities in the United States, South America, Asia, and Europe, BioMarin has a diversified global footprint, enhancing its market reach and operational resilience.
BioMarin's focus on responsible operations, efficiency improvements, and environmental impact reduction aligns with growing investor demand for sustainable and ethical business practices.
Trailing total returns as of 9/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $1.20+26.7% vs $0.95 | $990M+6.2% vs $932M |
Q2 2026 May 4, 2026 | $0.76-2.6% vs $0.78 | $766M+1.8% vs $753M |
Q1 2026 Feb 23, 2026 | -$0.24-241.7% vs $0.17 | $875M+4.9% vs $834M |
Q4 2025 Oct 27, 2025 | -$0.16-6.7% vs -$0.15 | $776M-0.2% vs $777M |
Q4 2026/ 2027 will be rich in catalysts for BioMarin Pharmaceutical Inc. From the presentation of 12 mg/kg BMN 351 Phase 1/2 data in Duchenne muscular dystrophy by year-end 2026 to a potential H1 2027 approval of Voxzogo for hypochondroplasia. BioMarin raised its full-year 2026 revenue guidance from $3.83 billion-$3.93 billion to $3.88 billion-$3.93 billion.
BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley's Global Healthcare Conference.
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark BMRN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioMarin Pharmaceutical Inc. (BMRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $64.06 | $12.38B | 35.59 | 12.87% | 10.83% | 5.94% | — | |
| $14.65 | $1.44B | -2.51 | 20.13% | -81.79% | — | — | |
| $20.12 | $2.12B | -2.82 | 15.58% | -6.93% | -9.96% | — | |
| $44.90 | $7.46B | -18.87 | 33.87% | -64.64% | -110.84% | — | |
| $26.40 | $4.52B | 11.53 | 11.87% | 33.42% | 32.39% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
BioMarin Pharmaceutical Inc. (BMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioMarin Pharmaceutical Inc. (BMRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 4, 2026·SEC
May 4, 2026·SEC
Get notified when BMRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioMarin Pharmaceutical Inc. (BMRN) stock FAQ — growth, dividends, profitability & financials explained
BioMarin Pharmaceutical Inc. (BMRN) reported $3.41B in revenue for fiscal year 2025. This represents a 283785% increase from $1.2M in 1998.
BioMarin Pharmaceutical Inc. (BMRN) grew revenue by 12.9% over the past year. This is steady growth.
Yes, BioMarin Pharmaceutical Inc. (BMRN) is profitable, generating $73.0M in net income for fiscal year 2025 (10.8% net margin).
BioMarin Pharmaceutical Inc. (BMRN) has a return on equity (ROE) of 5.9%. This is below average, suggesting room for improvement.
BioMarin Pharmaceutical Inc. (BMRN) generated $738.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
